Skip to main content
Top
Published in: Rheumatology International 4/2005

01-05-2005 | Original Article

Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation

Authors: Dursun Dursunoğlu, Harun Evrengül, Bülent Polat, Halil Tanrıverdi, Veli Çobankara, Asuman Kaftan, Mustafa Kılıç

Published in: Rheumatology International | Issue 4/2005

Login to get access

Abstract

Objectives

Changes in lipid profiles, Lp(a) lipoprotein, and acute phase reactants are associated with early atherosclerosis in rheumatoid arthritis (RA). The associations of Lp(a) levels with atherosclerotic disorders, diabetes, RA, and renal diseases suggest that Lp(a) might be involved in autoimmune reactions.

Methods

Eighty-seven women with RA diagnosed according to American Rheumatism Association criteria (mean age 45.4±9.4 years) were recruited and 50 healthy women (mean age 44±10.7 years) included as a control group. Serum Lp(a), total cholesterol (TC), triglyceride (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and C-reactive protein levels were analyzed.

Results

In the RA and C groups, serum Lp(a) levels were 39.2±20.6 mg/dl and 14.8±9.7 mg/dl, respectively (P<0.001). The TC levels were 188.4±41.8 mg/dl and 185.3±19.3 mg/dl (P>0.05), TG levels were 124.5±50.1 mg/dl and 94.6±24.9 mg/dl (P<0.01), HDL-C levels were 40.0±7.4 mg/dl and 52.8±4.8 mg/dl (P<0.01), and LDL-C levels were 123.4±24.6 mg/dl and 113.3±21.1 mg/dl (P>0.05). While serum CRP levels showed a positive correlation with Lp(a), they correlated negatively with HDL-C levels (r=0.83 and P<0.0001, r=−0.49 and P<0.0001, respectively). It was meaningful that Lp(a) correlated negatively with serum HDL-C level (r=−0.36, P<0.001).

Conclusions

It is suggested that higher serum Lp(a), lower HDL-C, higher TG level, and a high ratio of TC/HDL-C might show high risk of atherosclerosis. Inflammation in RA may cause changes in HDL-C and Lp(a) metabolisms.
Literature
1.
go back to reference Isomaki HA, Mutru O, Koota K (1975) Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 4:205–208PubMed Isomaki HA, Mutru O, Koota K (1975) Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 4:205–208PubMed
2.
go back to reference Abruzzo JL (1982) Rheumatoid arthritis and mortality. Arthritis Rheum 25:1020–1023PubMed Abruzzo JL (1982) Rheumatoid arthritis and mortality. Arthritis Rheum 25:1020–1023PubMed
3.
go back to reference Prior P, Symmons DPM, Scott DL, Brown R, Hawkins CF (1984) Causes of death in rheumatoid arthritis. Br J Rheumatol 23:92–99PubMed Prior P, Symmons DPM, Scott DL, Brown R, Hawkins CF (1984) Causes of death in rheumatoid arthritis. Br J Rheumatol 23:92–99PubMed
4.
go back to reference Mutro O, Laakso M, Isomaki H, Koota K (1985) Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ 290:1811–1813PubMed Mutro O, Laakso M, Isomaki H, Koota K (1985) Ten year mortality and causes of death in patients with rheumatoid arthritis. BMJ 290:1811–1813PubMed
5.
go back to reference Wallberg-Jonsson S, Cederfelt M, Rantapää-Dahlqvist S (2000) Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow up study. J Rheumatol 27:71–75PubMed Wallberg-Jonsson S, Cederfelt M, Rantapää-Dahlqvist S (2000) Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year follow up study. J Rheumatol 27:71–75PubMed
6.
go back to reference Scanu AM (1992) Lipoprotein (a): a genetic risk factor for premature coronary heart disease. JAMA 267:3326–3329CrossRefPubMed Scanu AM (1992) Lipoprotein (a): a genetic risk factor for premature coronary heart disease. JAMA 267:3326–3329CrossRefPubMed
7.
go back to reference Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. Am J Med 62:707–714CrossRefPubMed Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR (1977) High density lipoprotein as a protective factor against coronary heart disease. Am J Med 62:707–714CrossRefPubMed
8.
go back to reference Rantapää-Dahlqvist S, Wallberg-Jonsson S, Dahlen G (1991) Lipoprotein (a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50:366–368PubMed Rantapää-Dahlqvist S, Wallberg-Jonsson S, Dahlen G (1991) Lipoprotein (a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50:366–368PubMed
9.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed
10.
go back to reference Assmann G, Schulte H, Cullen P (1997) New and classical risk factors-the Munster Heart study (PROCAM). Eur J Med Res 2:237–242PubMed Assmann G, Schulte H, Cullen P (1997) New and classical risk factors-the Munster Heart study (PROCAM). Eur J Med Res 2:237–242PubMed
11.
go back to reference Lakatos J, Harsagyi A (1988) Serum total HDL, LDL cholesterol and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 21:93–96PubMed Lakatos J, Harsagyi A (1988) Serum total HDL, LDL cholesterol and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 21:93–96PubMed
12.
go back to reference Svensson K, Lithel H, Hallgren R, Selinus I, Vesby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Relativity to inflammatory activity. Arch Intern Med 147:1912–1916CrossRefPubMed Svensson K, Lithel H, Hallgren R, Selinus I, Vesby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Relativity to inflammatory activity. Arch Intern Med 147:1912–1916CrossRefPubMed
13.
go back to reference Lorber M, Aviram M, Linn S, Scharf Y, Brook JG (1985) Hypocholesterolemia and abnormal high density lipoprotein in rheumatoid arthritis. Br J Rheumatol 24:250–255PubMed Lorber M, Aviram M, Linn S, Scharf Y, Brook JG (1985) Hypocholesterolemia and abnormal high density lipoprotein in rheumatoid arthritis. Br J Rheumatol 24:250–255PubMed
14.
go back to reference Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Song CH, Lee J (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704PubMed Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Song CH, Lee J (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704PubMed
15.
go back to reference Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y (1999) Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 42:443–447CrossRefPubMed Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y (1999) Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 42:443–447CrossRefPubMed
16.
go back to reference Seriolo B, Accardo S, Cutolo M (1996) Lipoprotein (a) and other risk factors for thrombosis in rheumatoid arthritis. J Rheumatol 23:194–196 Seriolo B, Accardo S, Cutolo M (1996) Lipoprotein (a) and other risk factors for thrombosis in rheumatoid arthritis. J Rheumatol 23:194–196
17.
go back to reference Seriolo B, Accardo S, Fasciolo D, Bertolini S, Cutolo M (1996) Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheumatol 14:593–599PubMed Seriolo B, Accardo S, Fasciolo D, Bertolini S, Cutolo M (1996) Lipoproteins, anticardiolipin antibodies and thrombotic events in rheumatoid arthritis. Clin Exp Rheumatol 14:593–599PubMed
18.
go back to reference Seriolo B, Accardo S, Fasciolo D, Sulli A, Bertolini S, Cutolo M (1995) Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis. Thromb Haemost 74:799–800PubMed Seriolo B, Accardo S, Fasciolo D, Sulli A, Bertolini S, Cutolo M (1995) Lipoprotein (a) and anticardiolipin antibodies as risk factors for vascular disease in rheumatoid arthritis. Thromb Haemost 74:799–800PubMed
19.
go back to reference Dahlen GH, Boman J, Birgander LS, Lindblom B (1995) Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 114:165–174CrossRefPubMed Dahlen GH, Boman J, Birgander LS, Lindblom B (1995) Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 114:165–174CrossRefPubMed
20.
go back to reference Dahlen GH (1994) Indications of an autoimmune component in Lp(a) associated disorders. Eur J Immunogenet 21:301–312PubMed Dahlen GH (1994) Indications of an autoimmune component in Lp(a) associated disorders. Eur J Immunogenet 21:301–312PubMed
21.
go back to reference Lee YH, Choi SJ, Ji JD, Seo HS, Song GG (2000) Lipoprotein (a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 19:324–325CrossRefPubMed Lee YH, Choi SJ, Ji JD, Seo HS, Song GG (2000) Lipoprotein (a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 19:324–325CrossRefPubMed
22.
go back to reference Banks MJ, Kitas GD (1999) Lipoprotein (a) levels and atherosclerosis in rheumatoid arthritis: comment on the article by Asanuma et al. Arthritis Rheum 42:2491–2492CrossRef Banks MJ, Kitas GD (1999) Lipoprotein (a) levels and atherosclerosis in rheumatoid arthritis: comment on the article by Asanuma et al. Arthritis Rheum 42:2491–2492CrossRef
23.
go back to reference Wallberg-Jonsson S, Uddhammar A, Dahlen G, Rantapää-Dahlqvist S (1995) Lipoprotein (a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Scand J Clin Lab Invest 55:309–315PubMed Wallberg-Jonsson S, Uddhammar A, Dahlen G, Rantapää-Dahlqvist S (1995) Lipoprotein (a) in relation to acute phase reaction in patients with rheumatoid arthritis and polymyalgia rheumatica. Scand J Clin Lab Invest 55:309–315PubMed
24.
go back to reference Dahlen GH (1994) Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis 108:111–126PubMed Dahlen GH (1994) Lp (a) lipoprotein in cardiovascular disease. Atherosclerosis 108:111–126PubMed
25.
go back to reference Ehnholm C, Garoff H, Renkonen O, Simons K (1972) Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma. Biochemistry 11:3229PubMed Ehnholm C, Garoff H, Renkonen O, Simons K (1972) Protein and carbohydrate composition of Lp(a) lipoprotein from human plasma. Biochemistry 11:3229PubMed
27.
go back to reference Magaro M, Altomonte L, Zoli A, Mirone L, Ruffini MP (1991) Serum lipid pattern and apolipoproteins (A-I and B-100) in active rheumatoid arthritis. Z Rheumatol 50:168–170PubMed Magaro M, Altomonte L, Zoli A, Mirone L, Ruffini MP (1991) Serum lipid pattern and apolipoproteins (A-I and B-100) in active rheumatoid arthritis. Z Rheumatol 50:168–170PubMed
28.
go back to reference Gianturco SH, Bradley WA (1994) Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol 5:313–315PubMed Gianturco SH, Bradley WA (1994) Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol 5:313–315PubMed
29.
go back to reference Svensson K, Lithell H, Hallgren R, Selinus I, Vessby B (1987) Altered serum lipoproteins and enhanced lipoprotein elimination in patients with rheumatoid arthritis and other chronic inflammatory arthritides. I. Relationship to the inflammatory activity. Arch Intern Med 147:1912–1916CrossRefPubMed Svensson K, Lithell H, Hallgren R, Selinus I, Vessby B (1987) Altered serum lipoproteins and enhanced lipoprotein elimination in patients with rheumatoid arthritis and other chronic inflammatory arthritides. I. Relationship to the inflammatory activity. Arch Intern Med 147:1912–1916CrossRefPubMed
30.
go back to reference Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890PubMed Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890PubMed
31.
go back to reference Rossner S, Lofmark C (1977) Dyslipoproteinemia in patients with active chronic polyarthritis: a study on serum lipoproteins and triglycerides clearance (intravenous fat tolerance test). Atherosclerosis 28:41–52PubMed Rossner S, Lofmark C (1977) Dyslipoproteinemia in patients with active chronic polyarthritis: a study on serum lipoproteins and triglycerides clearance (intravenous fat tolerance test). Atherosclerosis 28:41–52PubMed
32.
go back to reference Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391PubMed Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391PubMed
33.
go back to reference Wallberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantapää-Dahlqvist S (1993) Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 12:318–324PubMed Wallberg-Jonsson S, Dahlen GH, Nilsson TK, Ranby M, Rantapää-Dahlqvist S (1993) Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 12:318–324PubMed
Metadata
Title
Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation
Authors
Dursun Dursunoğlu
Harun Evrengül
Bülent Polat
Halil Tanrıverdi
Veli Çobankara
Asuman Kaftan
Mustafa Kılıç
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2005
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-004-0438-0

Other articles of this Issue 4/2005

Rheumatology International 4/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.